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Figure 2. Blockade of ST2 shifts the Th1/Th2 balance toward Th2 phenotype and increases CD4D regulatory T cells. Spleen T cells were collected for intracellular
staining at day l0 post-transplantation. *p<0.05, **p<0.01.
Figure 3. Anti-ST2 mAb treatment preserves substantial GVL activity. (A) Survival cure. (B) GVHD score (bars) and percent of tumor relapse (lines). **p<0.01, IgG vs
Anti-ST2
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shifted Th1/Th2 balance toward a Th2 phenotype (Fig. 2).
In addition, ST2 blockade also induced expansion of
regulatory T cells (Tregs) (Fig. 2).
Given that anti-ST2 administration also up-regulated
expression of genes, such as Granzyme A, that can mediate
graft vs. leukemia (GVL) responses (Fig. 1E), we postulated
that ST2 blockade would not affect therapeutic GVL activity.
To conﬁrm this, we developed a clinically relevant model of
leukemia, in which C3H.SW recipients were challenged
with syngeneic GFP+ MLL-AF9 induced acute myeloid
leukemia cells. Our results indicated that administration of
anti-ST2 preserved substantial GVL activity and resulted in
signiﬁcantly improved leukemia-free survival (Fig. 3),
suggesting that anti-ST2 ameliorated GVHD and maintained
GVL response.
In summary, we found that prophylaxis with anti-ST2
antibody could alleviate GVHD severity and mortality whilepreserving GVL effect. ST2 blockade increased the level of
plasma IL-33, skewed the Th1/Th2 balance toward a Th2
phenotype, and induced Foxp3+Tregs (with preserved
expression of membrane ST2 [not shown]). Our ﬁndings
suggest that ST2 is a novel therapeutic target to ameliorate
GVHD.GRAFT PROCESSING
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Washington, DCFigure 1. Survival by Original HLA Match.The therapeutic use of T cells has long been studied to
boost HIV-speciﬁc T-cell immunity in HIV+ individuals.
However, clinical efﬁcacy has been relatively modest.
Infusion of single-epitope speciﬁc CD8 T cells showed safety
but could not provide lasting viral control, most likely due
to their restricted speciﬁcity. Recently, the development of
HIV entry resistant cells by other groups (e.g. CCR5 deletion)
has allowed T cell therapy to be even more feasible for HIV.
We hypothesized that broadly HIV-speciﬁc T cells could be
expanded from patients on antiretrovirals (ARVs) as well as
HIV negative individuals to effectively target HIV infection
using a non-HLA restricted approach for patients receiving
an autologous or allogeneic HSCT for HIV-associated
hematologic diseases. PBMCs from healthy donors or
HIV+ patients were stimulated with gag, pol, and nef pep-
tide libraries (pepmixes) in the presence of co-stimulatory
and growth factors. T cells expanded to clinically relevant
numbers (Mean¼1.62e8 cells, Range¼3.72e7-2.87e8 cells,
n¼7) even in the presence of ARVs. 5 of 7 patient sample
lines showed speciﬁc activity to all 3 HIV antigens in IFNY
ELISPOT assays. The T cells were broadly speciﬁc to gag
(99.33 SFC/10e5 cells), pol (131.11 SFC) and nef (337.26 SFC).
HIV-speciﬁc T cells were also expanded from 9 healthy (HIV
negative) donors. Expanded T cells released IFNg in
response to gag (163.79 SFC, n¼9) and nef (291.25 SFC, n¼6)
but not an irrelevant antigen (7.0 SFC). Importantly, T cells
expanded from both HIV+ and HIVneg were cytotoxic, as
expanded T cells lysed HIV antigen loaded autologous PHA
blasts (mean¼67.55% speciﬁc lysis at 10:1 effector:target
ratio) but not PHA blasts alone (0.46% speciﬁc lysis at 10:1
effector target ratio). Expanded T cells from HIV+ patients
also showed a greater ability to suppress HIV outgrowth in
vitro compared to unexpanded CD8+ T cells when
co-cultured with autologous, reactivated resting CD4+ T
cells, the authentic latent reservoirs. In 5 patients, a lower
recovery of virus from resting CD4+ cells was seen in the
presence of CTLs as compared to no effectors (p<0.006 by
Mann Whitney), while the non-speciﬁc CD8+ T-cells
showed only a modest trend towards decreased recovery
(p>0.9). Similarly, HIV-speciﬁc T cells derived from HIVneg
donors were able to suppress HIV replication more than
non-speciﬁc CD8+ T-cells when co-cultured with autolo-
gous CD4+ T cells infected with HIVSF162 (HIV only
p24¼681.95 pg/mL, nonspeciﬁc CD8+ T-cells¼448.80 pg/
mL, expanded CTL¼145.82 pg/mL). In summary, we have
developed robust GMP-compliant methodology for
expanding functional HIV-speciﬁc T cells from both HIV+
and HIVneg donors for use after autologous and allogeneic
HSCT, respectively. We now plan to translate our approach
to the clinical setting where we will test HIV-polyspeciﬁc T
cell products as a part of a strategy to fully eradicate HIV
infection after HSCT.HISTOCOMPATIBILITY/ALTERNATIVE STEM CELL SOURCES
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Background: Current practice in choosing potential donors
for umbilical cord blood transplantation (UCBT) involves
matching at the antigen level for HLA-A and HLA-B by
low-resolution (LR) typing and at the allele level for
HLA-DRB1 by high-resolution (HR) typing.
Objectives: To determine the signiﬁcance of HR HLA
matching on UCBT outcome in 62 eligible pediatric patients
<¼21 years-of-age. We further explored the presence of
anti-HLA antibodies (AHA) in our patient population.
Design/Method: Through IRB approved retrospective chart
review, we identiﬁed 62 UCBT recipients (>¼2.0X10 ˇ7TNC/
kg) for malignant (53%) and non-malignant (47%) disorders.
We compared original HLA typing (LR HLA-A-B; HR
HLA-DRB1) to HR HLA typing (HR HLA-A-B-C-DRB1). We
determined incidence of engraftment, relapse, acute and
chronic graft-versus-host disease (GVHD), early transplant-
related infections and mortality (from any cause and non-
relapse/non-disease progression mortality) and analyzed
each of these variables against subgroups of HR and
original HLA matching using the Fisher exact test. Lastly, we
determined the presence of pre-UCBT AHA.
Results: Retrospective determination of HR HLA matching
showed 16% of pairs were matched at all HR loci; 6% were
mismatched at 1,14% at 2, 29% at 3, 27% at 4, 3% at 5, and 2% at
both 6 and 7 alleles. Ten of 13 (77%) transplants originally
matched at LR HLA-A-B and HR HLA-DRB1 remained
matched at the allelic level (HR HLA-A-B-C-DRB1).
